Article: New England Journal of Medicine Publishes First Clinical Study of Medication to Improve Wakefulness in Patients with Shift Work Sleep Disorder.

Study Shows that PROVIGIL(R) (modafinil) Tablets [C-IV] Improves Patients' Ability to Remain Awake and Alert

FRAZER, Pa., Aug. 3 /PRNewswire-FirstCall/ -- Cephalon, Inc. today announced that results of its pivotal Phase three study of PROVIGIL in patients with shift work sleep disorder (SWSD) has been published in this week's New England Journal of Medicine. In the first ever clinical study of SWSD, patients taking PROVIGIL showed improvements in their wakefulness, performance and level of attention.

"This study further clarifies the role excessive sleepiness plays in shift work sleep disorder, and the value of PROVIGIL in treating excessive sleepiness," said Dr. ...






Related newspaper, magazine, and journal articles:

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!